Breast Cancer
Conditions
Brief summary
The purpose of this study is to evaluate the efficacy and safety of E7389 in Patients with locally advanced or metastatic breast cancer, previously treated with anthracycline, taxane, and capecitabine as prior therapy, and who are refractory to the last prior therapy for their disease.
Interventions
DRUGE7389
E7389 1.4 mg/m\^2 intravenous bolus given over 2-5 minutes on Days 1 and 8 every 21 days.
Sponsors
Eisai Limited
Eisai Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Female patients with histologically or cytologically confirmed carcinoma of the breast. Every effort should be made to make paraffin embedded tissue or slides from the diagnostic biopsy or surgical specimen available for confirmation of diagnosis. 2. Patients with locally advanced or metastatic disease who have received at least two (and not more than five) prior chemotherapeutic regimens for breast cancer, at least one of which was administered for treatment of locally advanced or metastatic disease. Prior therapy must be documented by the following criteria prior to entry onto study: * Regimens must have included an anthracycline (eg, doxorubicin, epirubicin), a taxane (eg, paclitaxel, docetaxel) and capecitabine in any combination or order. * One or two of these regimens may have been administered as adjuvant and/or neoadjuvant therapy. * Patients with human epidermal growth factor receptor 2 (HER2/neu) over-expressing tumors must additionally have been treated with trastuzumab. * Patients with estrogen receptor-expressing tumors may have additionally been treated with estrogen-specific therapy. * Prior hormonal therapy, biological therapy, (eg, trastuzumab, bevacizumab), or immunotherapy, is not to be counted as one of the 2 to 5 prior chemotherapy regimens allowed. However, hormonal therapy must be discontinued one week before administration of E7389, and biological therapy must be discontinued two weeks before E7389 administration. * Patients who are being treated with bisphosphonates when they enter the study are allowed to continue the medication as long as the dosing does not change. In case a change in dosing is deemed necessary, the case needs to be discussed with the Sponsor. 3. Progression on or within six months of the last regimen for advanced disease, documented by the following: * The dates of treatment, doses, outcome of therapy and the reason for discontinuation of prior anthracycline, taxane, capecitabine, and trastuzumab therapy must be provided. * Prior to entry onto the study, information ensuring that the last therapy fulfills eligibility criteria is required, which includes progression while receiving this last prior chemotherapy regimen, or within six months of receiving that therapy. * Chemotherapy medication administration sheets or other official medical/hospital records indicating type and dates of chemotherapy must be available for inspection, and one of the following as a reason for discontinuation of medication is required: radiographic evidence of progression, or doctor's office or hospitalization notes documenting radiologic progression, clinically documented increase in tumor burden, and/or increase in tumor-specific markers. 4. Patients with measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria, defined as at least one lesion that can be accurately measured in at least one diameter (at least 10 mm in longest diameter \[LD\] by spiral computer tomography \[CT\] scan), or at least 20 mm by standard techniques. If the only measurable lesion is a lymph node, it must measure at least 20 mm in LD. If a single lesion is identified as the target lesion, a biopsy or aspiration with cytological or histological confirmation of the diagnosis of breast carcinoma is required. 5. Resolution of all chemotherapy or radiation-related toxicities to less than Grade 2 severity, except for stable sensory neuropathy ≤ Grade 2 and alopecia. 6. Age \>= 18 years. 7. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2. 8. Life expectancy of ≥ 3 months. 9. Adequate renal function as evidenced by serum creatinine ≤ 2.0 mg/dL or calculated creatinine clearance ≥ 40 mL/minute (min) per the Cockcroft and Gault formula. 10. Adequate bone marrow function as evidenced by absolute neutrophil count (ANC) ≥1.5 x 10\^9/L hemoglobin ≥ 10.0 g/dL (acceptable if it is corrected by therapeutic intervention or transfusional support), and platelet count ≥ 100 x 10\^9/L. 11. Adequate liver function as evidenced by bilirubin ≤ 1.5 mg/dL and alkaline phosphatase, alanine transaminase (ALT), and aspartate transaminase (AST) ≤ 3 times the upper limits of normal (ULN) (in the case of liver metastases ≤ 5 x ULN), unless there are bone metastases, in which case liver specific alkaline phosphatase must be separated from the total and used to assess the liver function instead of the total alkaline phosphatase. 12. Willing and able to complete the European Organization for Research on the Treatment of Cancer (EORTC) quality of life assessment, Analgesic Diary, and Pain Visual Analog Scale (VAS). 13. Willing and able to comply with the study protocol for the duration of the study. 14. Written informed consent prior to any study-specific screening procedures with the understanding that the patient may withdraw consent at any time without prejudice.
Exclusion criteria
1. Patients must not have received chemotherapy, radiation, or biologic therapy within two weeks, hormonal therapy within one week, or trastuzumab within three weeks, before E7389 treatment start. 2. Patients must not have received radiation therapy encompassing \> 30% of marrow (a lesion that has been irradiated cannot be used as a target lesion, unless it has progressed after the irradiation). 3. Patients must not have pre-existing neuropathy \> Grade 2. 4. Patients must not have participated in a prior E7389 clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate | Every two cycles | Based on Response Evaluation Criteria in Solid Tumors (RECIST), consisting of complete response (CR) plus partial response (PR). Defined as the best response from the start of treatment until disease progression or recurrence. Lesions measured by computed tomography (CT) scan and magnetic resonance imaging (MRI). Objective response rate: complete response (CR-disappearance of all lesions)+ partial response (PR-30% decrease in lesion diameter), Progressive Disease (PD-20% increase in lesion diameter), stable disease (SD-neither shrinkage nor increase of lesions). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Duration of Response | From first documented complete or partial response until disease progression or death | Complete response (CR) is defined as the disappearance of all lesions. Partial response (PR) is defined as 30% decrease in lesion diameter. |
Countries
Canada, United States
Participant flow
Recruitment details
This study was recruited at 42 centers in US and 36 centers in EU during the period of Oct 2005 to Sep 2007.
Participants by arm
| Arm | Count |
|---|---|
| E7389 1.4 mg/m^2 E7389 1.4 mg/m\^2 intravenous bolus given over 2-5 minutes on Days 1 and 8 every 21 days. | 291 |
| Total | 291 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Adverse Event | 25 |
| Overall Study | Clinical Progression | 30 |
| Overall Study | Not Otherwise Specified | 10 |
| Overall Study | Physician Decision | 11 |
| Overall Study | Progressive Disease | 212 |
| Overall Study | Withdrawal by Subject | 7 |
Baseline characteristics
| Characteristic | E7389 1.4 mg/m^2 |
|---|---|
| Age, Continuous | 55.4 years STANDARD_DEVIATION 10.8 |
| Race/Ethnicity, Customized Asian/Pacific Islander | 6 participants |
| Race/Ethnicity, Customized Black or African American | 12 participants |
| Race/Ethnicity, Customized Other | 8 participants |
| Race/Ethnicity, Customized Unknown or Not Reported | 66 participants |
| Race/Ethnicity, Customized White | 199 participants |
| Sex: Female, Male Female | 291 Participants |
| Sex: Female, Male Male | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 290 / 291 |
| serious Total, serious adverse events | 88 / 291 |
Outcome results
Primary
Objective Response Rate
Based on Response Evaluation Criteria in Solid Tumors (RECIST), consisting of complete response (CR) plus partial response (PR). Defined as the best response from the start of treatment until disease progression or recurrence. Lesions measured by computed tomography (CT) scan and magnetic resonance imaging (MRI). Objective response rate: complete response (CR-disappearance of all lesions)+ partial response (PR-30% decrease in lesion diameter), Progressive Disease (PD-20% increase in lesion diameter), stable disease (SD-neither shrinkage nor increase of lesions).
Time frame: Every two cycles
Population: Eligible Population
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| E7389 1.4 mg/m^2 | Objective Response Rate | 14.1 Percentage of Participants |
Secondary
Duration of Response
Complete response (CR) is defined as the disappearance of all lesions. Partial response (PR) is defined as 30% decrease in lesion diameter.
Time frame: From first documented complete or partial response until disease progression or death
Population: Eligible Population
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| E7389 1.4 mg/m^2 | Duration of Response | 176 Days |